EWEwa Wojtanowska

Ewa Wojtanowska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ewa Wojtanowska has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ORAL GnRH RECEPTOR ANTAGONISTS IN THE TREATMENT OF ENDOMETRIOSIS: CURRENT EVIDENCE AND FUTURE THERAPEUTIC PERSPECTIVES

    by Karolina Grodkowska-Szukała, Vanessa Gąsiorowska, Ewa Jachimczak, Paulina Jaruga, Natalia Smyczyńska, Mateusz Michalak, Julia Paczyna, Ewa Wojtanowska, Julia Kozicka, Marcin Mazur

    Endometriosis is a chronic, estrogen-dependent systemic disease that significantly impairs women's quality of life and remains a major therapeutic challenge due to frequent symptom recurrence and the limitations of currently available treatments. This review aimed to summarize current evidence regarding the efficacy, safety, and clinical role of oral gonadotropin-releasing hormone (GnRH) antagonists in the management of endometriosis-associated pain. A literature search was conducted using the PubMed and Cochrane Library databases with the terms “endometriosis,” “GnRH antagonists,” “elagolix,” “relugolix,” and “linzagolix.” Relevant prospective and retrospective studies, systematic reviews, meta-analyses, and landmark publications providing essential background on the pathophysiology of endometriosis and the mechanism of action of GnRH antagonists were included. Current evidence indicates that oral GnRH antagonists provide rapid, reversible, and dose-dependent suppression of ovarian estrogen production without the initial flare effect observed with GnRH agonists. Clinical trials have demonstrated significant reductions in dysmenorrhea, non-menstrual pelvic pain, and dyspareunia, accompanied by improvements in health-related quality of life and reductions in analgesic use. The availability of different dosing strategies and add-back therapy enables individualized treatment while minimizing hypoestrogenic adverse effects, including bone mineral density loss. Despite their favorable efficacy and safety profile, treatment remains limited by high costs, the need for long-term monitoring, and the lack of direct comparisons with standard hormonal therapies. Oral GnRH antagonists represent an important advancement in the pharmacological management of endometriosis and offer a promising option for long-term individualized treatment, particularly in women with persistent symptoms or resistance to conventional hormonal therapy.

  • Open Access

    ARTIFICIAL INTELLIGENCE-ENHANCED LIQUID BIOPSY IN CANCER MONITORING: FROM TREATMENT RESPONSE TO EARLY DETECTION OF DISEASE RECURRENCE

    by Vanessa Gąsiorowska, Karolina Grodkowska-Szukała, Ewa Jachimczak, Natalia Smyczyńska, Ewa Wojtanowska, Paulina Jaruga, Julia Paczyna, Julia Kozicka, Mateusz Michalak, Marcin Mazur

    Liquid biopsy has emerged as an important minimally invasive technology in contemporary oncology, enabling repeated assessment of tumor-derived molecular information through blood and other biological fluids. Circulating tumor DNA (ctDNA), circulating tumor cells, cell-free DNA methylation patterns, extracellular vesicles, circulating RNA and fragmentomic signatures may provide dynamic information about tumor burden, treatment response, molecular residual disease and cancer recurrence. However, liquid biopsy generates complex, multidimensional datasets in which tumor-derived signals may be extremely small relative to biological and technical background. Artificial intelligence (AI), including machine learning and deep learning, offers a potential computational framework for integrating these heterogeneous signals and generating clinically meaningful predictions. This review examines the emerging convergence of AI and liquid biopsy, with particular emphasis on longitudinal cancer monitoring rather than cancer detection alone. The available PubMed-indexed literature was reviewed to evaluate the potential role of AI-enhanced liquid biopsy in treatment-response assessment, minimal residual disease detection, prediction of treatment resistance and early identification of disease recurrence. Evidence from colorectal, lung, breast, hepatocellular and other solid tumors is discussed. The review also addresses major translational barriers, including low tumor shedding, clonal hematopoiesis, analytical heterogeneity, external validation, algorithmic bias, interpretability, data privacy, cost and uncertainty regarding clinical actionability. Current evidence indicates that AI can extract complementary biological information from complex circulating biomarker datasets, but prospective validation is still required before widespread implementation. AI-enhanced liquid biopsy may ultimately support a transition from episodic, imaging-centered surveillance toward personalized, dynamic and molecularly informed cancer monitoring.

  • Open Access

    OPTIMIZING PROSTATE CANCER DIAGNOSTICS: CAN BIOMARKERS DECREASE THE BURDEN OF OVER-INVESTIGATION?

    by Mikolaj Kurczynski, Aleksandra Suszczyńska, Angelika Wiatr, Ksenia Jakubiak, Julia Witkowska, Ewa Wojtanowska, Aleksandra Pietrucień, Monika Krasoń

    The foundation of current prostate cancer diagnostics still remains the interpretation of total PSA (tPSA) results, but it is an imperfect test due to its low specificity and diagnostic ambiguities in patients within the "gray zone," meaning patients with a result of (2.0/4.0–10.0 ng/mL). This fact leads to many cases of "overdiagnosis" and an excess of unnecessarily performed biopsies. This article summarizes the diagnostic value of blood-based biomarkers and tests (PHI, 4Kscore, Stockholm3) as well as urine-based ones (SelectMDx and ExoDx). These tests achieve high AUC values (0.76–0.88) and a high negative predictive value (up to 98%) in detecting clinically significant prostate cancer (csPCa, GG ≥ 2), underscoring their advantage over traditional methods. Combining them with multiparametric MRI allows for a 30–65% reduction in unnecessary biopsies while maintaining high oncological safety for the patient. Despite promising results, the high costs of individual tests, lack of reimbursement, and absence of full standardization in international urological guidelines remain a continuous challenge and a hurdle to their introduction into daily practice.

  • Open Access

    HORMONALLY INDUCED GINGIVAL ENLARGEMENT: FOCUS ON EPULIS - A NARRATIVE REVIEW

    by Aleksandra Suszczyńska, Ewa Wojtanowska, Marcin Mazur, Julia Kozicka, Angelika Wiatr, Patryk Ziomek, Natalia Tomoń

    Gingival enlargement and epulis are common reactive lesions of the oral cavity with a multifactorial aetiology. While dental plaque is considered the primary initiating factor, systemic hormonal influences play a significant modulatory role in their development and clinical expression. This narrative review aims to summarise current evidence regarding the effects of sex steroid hormones on gingival enlargement and epulis, with particular emphasis on pregnancy-associated lesions and hormonal fluctuations throughout life. A literature search was conducted using PubMed and Google Scholar, focusing on studies investigating the effects of oestrogen and progesterone on periodontal tissues. The available evidence indicates that sex hormones influence inflammatory responses, vascular function, immune activity, microbial composition, and connective tissue metabolism within the periodontium. The findings suggest that hormonal changes do not directly initiate gingival disease but act as modifying factors that increase tissue susceptibility to local irritants, particularly dental plaque. Understanding these mechanisms is essential for improving prevention and clinical management of hormonally influenced gingival conditions.

  • Open Access

    INNOVATIVE ORGANIZATIONAL STRATEGIES IN MANAGING ICU DELIRIUM: MITIGATING NURSING BURNOUT AND IMPROVING CRITICAL CARE QUALITY

    by Julia Paczyna, Ewa Jachimczak, Ewa Wojtanowska, Paulina Jaruga, Karolina Grodkowska-Szukała, Julia Kozicka, Marcin Mazur, Vanessa Gąsiorowska

    Background and Aim: Delirium in the Intensive Care Unit (ICU) is a complex dysfunction that poses not only a clinical threat but also a massive organizational challenge, affecting the quality of care and staff well-being. This review aims to systematize knowledge on innovative strategies for delirium management, with a specific focus on mitigating nursing burnout and implementing the integrated ABCDEF bundle as an organizational protocol in light of the PADIS (2025) and ESAIC (2024) guidelines. Methodology: A narrative literature review (2015–2026) was conducted using PubMed/MEDLINE, Scopus, and the Cochrane Library, focusing on management innovations, burnout research, and non-pharmacological interventions. Results: Traditional, pharmacologically driven methods fail to yield expected results, and the growing workload drives a severe staffing crisis. The application of the integrated ABCDEF bundle (early mobilization, analgosedation optimization) as a structural innovation in daily workflow reduces delirium incidence by 50%. The routine use of antipsychotic medications neither improves patient outcomes nor relieves system burdens. Conclusion: Combating delirium requires a transformation of the organizational culture within the ICU. Implementing the "Awake and Walking ICU" concept significantly improves patient outcomes, mitigates the socio-economic impact of Post-Intensive Care Syndrome (PICS), and effectively protects nursing staff from severe occupational burnout.

  • Open Access

    IRON DEFICIENCY AND ‘SPORTS ANAEMIA’ IN YOUNG FEMALE ATHLETES

    by Julia Kozicka, Marcin Mazur, Ewa Wojtanowska, Ewa Jachimczak, Paulina Jaruga, Karolina Grodkowska-Szukała, Julia Paczyna, Vanessa Gąsiorowska, Aleksandra Suszczyńska, Hanna Klimczyk

    Iron deficiency, including non-anaemic iron deficiency (NAID), is a common problem among young, menstruating female athletes, requiring precise differentiation from ‘athlete’s anaemia’, which is a physiological adaptive haemodilution. The aim of this narrative review was to summaries the mechanisms, prevalence, diagnostic principles, and clinical and performance-related consequences of these disorders. Epidemiological data indicate that hypoferritinaemia (ferritin ≤30 ng/mL) affects up to 47% of young female athletes, and 23.1% develop overt anaemia according to WHO criteria. The Pathomechanism of the negative iron balance is multifactorial and includes losses through sweat, gastrointestinal micro bleeding, mechanical haemolysis, and exercise-induced increases in interleukin-6 and hepcidin, which temporarily block intestinal iron absorption and recycling. It has also been shown that aerobic training is associated with a poorer haematological profile than anaerobic training. The consequences of NAID extend beyond reduced physical performance and fatigue, also including a decrease in bone mineral density and an increased risk of stress injuries to the lower limbs. In laboratory diagnostics, haemoglobin alone has been shown to have low sensitivity, which justifies routine measurement of ferritin (with the sports threshold raised to <30–35 ng/mL), sTfR and TSAT. In summary, optimal therapeutic management should be holistic, encompassing the provision of adequate energy intake, monitoring of vitamin levels (D, B12, folic acid) and targeted, 6–8-week course of oral supplementation in confirmed cases, whilst strictly avoiding the routine administration of high doses and intravenous infusions without clear laboratory indications.

  • Open Access

    CONTEMPORARY AND EMERGING TREATMENT STRATEGIES FOR GLIOBLASTOMA: INTEGRATION OF SURGICAL, LOCAL, AND MOLECULAR APPROACHES

    by Paulina Jaruga, Ewa Jachimczak, Vanessa Gąsiorowska, Karolina Grodkowska-Szukała, Julia Paczyna, Ewa Wojtanowska, Julia Kozicka, Marcin Mazur, Mateusz Michalak, Natalia Smyczyńska

    Glioblastoma is the most common and most aggressive primary malignant tumor of the central nervous system in adults and remains associated with a very poor prognosis despite multimodal treatment. The current standard of care consists of maximal safe surgical resection followed by radiotherapy and temozolomide-based chemotherapy; however, the effectiveness of this strategy is limited by marked tumor heterogeneity, the infiltrative growth pattern, the presence of the blood–brain barrier, and the immunosuppressive tumor microenvironment. The aim of this paper is to review current standards of GBM treatment as well as emerging therapeutic strategies under development. Analysis of the available evidence indicates that novel approaches such as intraoperative 18F-FET PET, intraoperative radiotherapy, local temozolomide delivery using hydrogel-based systems, intranasal drug administration, NanoTherm® therapy, and CAR-T immunotherapy may increase treatment precision, improve local tumor control, and partially overcome the limitations of systemic therapy. However, most of these methods remain investigational or experimental, and their actual impact on overall survival requires further validation. The integration of advanced imaging, local treatment modalities, and molecularly targeted therapies appears to be the most promising direction for future GBM management.

  • Open Access

    MODERN ASSESSMENT OF PROGRESSION RISK IN INTERSTITIAL LUNG DISEASES (ILD): QUANTITATIVE COMPUTED TOMOGRAPHY (qCT), BIOMARKERS, AND ARTIFICIAL INTELLIGENCE IN CLINICAL PRACTICE

    by Marcin Mazur, Julia Kozicka, Ewa Wojtanowska, Ewa Jachimczak, Paulina Jaruga, Karolina Grodkowska-Szukała, Julia Paczyna, Vanessa Gąsiorowska, Aleksandra Suszczyńska

    Interstitial lung diseases (ILD) constitute a heterogeneous group of conditions with a complex clinical course, in which accurate prediction of the rate of fibrosis is crucial for optimizing therapy. However, traditional diagnostic methods, which are based on visual assessment of high-resolution computed tomography (HRCT) and pulmonary function tests (PFT), are burdened by significant inter-observer variability and limited sensitivity in detecting early structural changes. This review of the literature from 2010-2026 analyzes the potential of innovative technologies, such as quantitative computed tomography (qCT), radiomics, and artificial intelligence (AI), in the process of risk assessment and monitoring of ILD progression. Scientific evidence indicates that qCT parameters, including normal lung volume percentage (NLV%) and fibrosis volume percentage (FLV%), offer an objective and reproducible measure of disease severity, showing a strong correlation with spirometric parameters (FVC, DLCO) and the risk of death in patients with idiopathic pulmonary fibrosis (IPF) or connective tissue diseases (CTD-ILD). Modern diagnostics increasingly utilize hybrid artificial intelligence models, which achieve an accuracy of 94-95% in differentiating morphological patterns. These methods are complemented by radiomics, which, by extracting hundreds of numerical features related to parenchymal texture heterogeneity, allows for the differentiation of fibrotic from inflammatory patterns with a precision unattainable by the human eye. Despite these promising prospects, the process of implementing these tools into clinical practice faces systemic barriers, such as technical variability among scanners, the lack of standardized image reconstruction protocols, and IT challenges related to integrating algorithms with hospital systems. A key prerequisite for the full implementation of AI and qCT in the care of patients with ILD is the conduct of multicenter prospective studies based on hard endpoints and the development of an international ethical and legal framework regulating responsibility for algorithm-assisted decisions.

  • Open Access

    THE IMPACT OF OBESITY ON THE DEVELOPMENT AND PROGRESSION OF SELECTED RESPIRATORY DISEASES — OBSTRUCTIVE SLEEP APNEA, ASTHMA, AND COVID-19

    by Ewa Wojtanowska, Ewa Jachimczak, Paulina Jaruga, Karolina Grodkowska-Szukała, Julia Kozicka, Julia Paczyna, Marcin Mazur, Vanessa Gąsiorowska, Aleksandra Suszczyńska, Angelika Wiatr

    Obesity (BMI ≥30 kg/m²) is a growing global health problem that significantly affects respiratory function and disease. Excess adipose tissue can alter lung mechanics, reducing respiratory system compliance and lowering functional residual capacity while increasing airway resistance, particularly when lying down. Concurrently, obesity promotes a chronic, low-grade inflammatory state through hypertrophic adipocytes and macrophage infiltration, resulting in the overproduction of cytokines (e.g. IL-6 and TNF-α), adipokines (e.g. leptin) and mediators (e.g. HMGB1). These mechanical and inflammatory changes contribute to airway remodelling, endothelial dysfunction and an increased susceptibility to chronic and infectious respiratory diseases. This review summarises the current evidence on the impact of obesity on asthma, obstructive sleep apnoea (OSA), and SARS-CoV-2 infection. In asthma, obesity defines a distinct phenotype that is often difficult to treat, characterised by more persistent disease, a reduced response to inhaled glucocorticoids and spirometric changes that improve with weight loss. In OSA, obesity — particularly central and visceral fat — narrows the upper airway, destabilises ventilatory control, and markedly increases disease prevalence and severity. Indices of abdominal adiposity correlate more strongly with apnoea–hypopnoea burden than BMI alone. In the context of SARS-CoV-2 infection, obesity is a major risk factor for severe disease, higher rates of hospitalisation, ICU admission, ARDS and death, with risk rising across obesity classes. Obese patients also more often require invasive ventilation or ECMO, and they may experience prolonged respiratory impairment and long-term symptoms of post-viral fatigue.

  • Open Access

    BLINATUMOMAB IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: MECHANISM OF ACTION, CLINICAL RELEVANCE, AND EMERGING THERAPEUTIC PERSPECTIVES

    by Ewa Jachimczak, Vanessa Gąsiorowska, Paulina Jaruga, Karolina Grodkowska, Ewa Wojtanowska, Julia Kozicka, Julia Paczyna, Marcin Mazur, Natalia Smyczyńska, Mateusz Michalak

    Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, and despite significant improvements in survival with intensive chemotherapy, relapse and minimal residual disease (MRD) remain major clinical challenges. Blinatumomab is a bispecific T-cell engager (BiTE) antibody targeting CD19-positive B-cell precursor ALL. By simultaneously binding CD3 on T lymphocytes and CD19 on leukemic cells, it enables major histocompatibility complex (MHC)-independent activation of cytotoxic T cells and targeted elimination of malignant cells. Clinical studies have demonstrated that blinatumomab is effective in inducing remission in relapsed or refractory pediatric ALL and in achieving molecular remission in MRD-positive patients. Compared with conventional chemotherapy, it shows improved efficacy and a more favorable toxicity profile, although cytokine release syndrome and neurotoxicity remain clinically relevant adverse events. Blinatumomab is increasingly used as a bridge to hematopoietic stem cell transplantation and is being investigated in combination regimens and earlier treatment settings. However, therapeutic resistance, including CD19 antigen loss and T-cell dysfunction, remains a limitation. Overall, blinatumomab represents a significant advancement in immunotherapy for pediatric ALL, bridging conventional chemotherapy and cellular therapies such as CAR-T.